Intellia Therapeutics, Inc. NTLA
NASDAQ Price as of Nov 17, 2026 · Fiscal year ended Dec 31, 2025 · Latest quarter Sep 30, 2026
Market cap
$1.37B
P/E (GAAP, TTM)
—
P/E (operating)
—
Dividend yield
0.0%
Revenue growth YoY
-48.0%
EPS growth YoY
1.1%
ROIC
-67.5%
Piotroski F-score
3
Three ways to read the P/E
P/E (GAAP, TTM)
—
Net income of the last 4 quarters. Includes investment gains and one-time items.
P/E (GAAP, annual)
—
Net income of the latest fiscal year. Includes investment gains and one-time items.
P/E (operating)
—
After-tax operating income only: the core business.
P/E (excl. gains)
—
Net income after removing identified investment and asset-sale gains.
How it has changed
Values as they were known at each quarter-end. Green = moved in the better direction, red = worse.
| Metric | 2026Q3 | 2026Q2 | Change QoQ | 2025Q3 | Change YoY |
|---|---|---|---|---|---|
| Revenue growth YoY (qtr) | -46.2% | -9.5% | -36.7 pts | 104.8% | -151.0 pts |
| EPS growth YoY (qtr) | 18.4% | 26.4% | -8.0 pts | 35.5% | -17.2 pts |
| Revenue growth (TTM) | 12.6% | 45.0% | -32.5 pts | 15.0% | -2.4 pts |
| EPS growth (TTM) | 28.8% | 32.7% | -3.9 pts | 14.6% | +14.2 pts |
| P/E (GAAP, TTM) | — | — | — | — | — |
| P/E (operating) | — | — | — | — | — |
| P/E (excl. gains) | — | — | — | — | — |
| P/B | 1.95 | 2.73 | -0.79 | — | — |
| ROIC | -67.5% | -67.5% | 0.0 pts | -61.8% | -5.7 pts |
| Net margin | -609.9% | -609.9% | 0.0 pts | -896.8% | +286.9 pts |
| Dividend yield | 0.0% | 0.0% | 0.0 pts | — | — |
| EPS (TTM) | -3.34 | -3.52 | +5.1% | -4.69 | +28.8% |
| Price | $12.05 | $16.93 | -28.8% | — | — |
History by quarter-end
Reported quarters
| Quarter ended | Revenue | QoQ | YoY | EPS | QoQ | YoY | Net margin |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $7.16M | -6.5% | -48.0% | -0.91 | -13.8% | 1.1% | -1,779.8% |
| Jun 30, 2026 | $7.66M | -49.1% | -46.2% | -0.80 | 1.2% | 18.4% | -1,392.3% |
| Mar 31, 2026 | $15.05M | -34.6% | -9.5% | -0.81 | 0.0% | 26.4% | -639.5% |
| Dec 31, 2025 * | $23.02M | 67.0% | 78.8% | -0.81 | 12.0% | 36.2% | -416.2% |
| Sep 30, 2025 | $13.78M | -3.3% | 51.3% | -0.92 | 6.1% | 31.3% | -735.2% |
| Jun 30, 2025 | $14.25M | -14.3% | 104.8% | -0.98 | 10.9% | 35.5% | -710.8% |
| Mar 31, 2025 | $16.63M | 29.2% | -42.5% | -1.10 | 13.4% | 1.8% | -687.6% |
| Dec 31, 2024 * | $12.87M | 41.3% | 771.6% | -1.27 | 5.2% | 13.6% | -1,001.2% |
| Sep 30, 2024 | $9.11M | 31.0% | -24.0% | -1.34 | 11.8% | 2.9% | -1,489.5% |
| Jun 30, 2024 | $6.96M | -76.0% | -48.8% | -1.52 | -35.7% | -8.6% | -2,112.6% |
| Mar 31, 2024 | $28.94M | 1,609.4% | 129.5% | -1.12 | 23.8% | 4.3% | -371.3% |
| Dec 31, 2023 * | -$1.92M | -116.0% | -114.1% | -1.47 | -6.5% | -6.5% | 6,894.2% |
* Q4 is not filed separately. It is calculated as the fiscal year minus the first three quarters.
All figures
Price & size
| Fiscal year end | Dec 31, 2025 | End date of the latest annual (10-K) report used. |
|---|---|---|
| Price date | Nov 17, 2026 | Date of the latest closing price used. |
| Price | $9.78 | Latest closing price. |
| Market cap | $1.37B | Price × shares outstanding. |
| Enterprise value | $1.22B | Market cap + debt − cash: the price of the whole business. |
| Shares | 140.36M | Shares outstanding used for market cap. |
Valuation
| P/E (GAAP, annual) | — | Price ÷ diluted earnings per share of the latest fiscal year. Uses NET income, so it includes investment gains and one-time items. Blank when earnings are negative. |
|---|---|---|
| P/E (GAAP, TTM) | — | Price ÷ the sum of the last four quarters of diluted EPS. Like P/E but more current. Includes investment gains and one-time items. |
| P/E (operating) | — | Market cap ÷ after-tax OPERATING income (latest fiscal year). Core business only: leaves out interest, investment gains and one-time items. |
| P/E (operating, TTM) | — | Market cap ÷ after-tax operating income of the last four quarters. |
| P/E (excl. gains) | — | Market cap ÷ net income after removing identified investment and asset-sale gains (after tax). Equals the GAAP P/E when no gains were identified. |
| PEG | — | P/E ÷ 3-year EPS growth rate (in %). Below 1 can mean growth is cheap. |
| PEG (TTM) | — | TTM P/E ÷ TTM EPS growth rate (in %). |
| Earnings yield | -30.1% | Net income ÷ market cap. The inverse of the P/E. |
| Earnings yield (TTM) | -34.0% | TTM EPS ÷ price. |
| P/B | 2.04 | Market cap ÷ shareholders' equity. Blank when equity is negative. |
| P/S | 20.29 | Market cap ÷ revenue of the latest fiscal year. |
| P/S (TTM) | 25.96 | Market cap ÷ revenue of the last four quarters. |
| P/FCF | — | Market cap ÷ free cash flow (operating cash flow − capital spending). Blank when FCF is negative. |
| EV/EBITDA | — | Enterprise value ÷ EBITDA. Useful for comparing companies with different debt levels. |
| EV/EBIT | — | Enterprise value ÷ operating income. |
| EV/Sales | 17.99 | Enterprise value ÷ revenue. |
| Book value / share | 4.78 | Shareholders' equity ÷ shares. |
| FCF yield | -28.8% | Free cash flow ÷ market cap. |
Operating vs. one-time earnings
| Operating EPS | -2.48 | After-tax operating income per share (latest fiscal year). |
|---|---|---|
| Investment gains | -$899.00K | Gains (+) or losses (−) on investments inside net income, when the company reported them with the standard tags. Blank = none identified. |
| Asset-sale gains | -$527.00K | One-time gains or losses from selling property, assets or businesses. Blank = none identified. |
| Non-operating income | — | Pre-tax income minus operating income: interest, investment results and one-time items combined. |
| Gains as % of net income | -0.3% | Identified investment and asset-sale gains (after tax) as a share of net income. A high value means reported earnings are flattered by non-core gains. |
Latest quarter & trailing 12 months
| Latest quarter | Sep 30, 2026 | End date of the most recent reported quarter. |
|---|---|---|
| Revenue (qtr) | $7.16M | Revenue of the latest reported quarter. |
| Net income (qtr) | -$127.49M | Net income of the latest reported quarter. |
| EPS (qtr) | -0.91 | Diluted EPS of the latest reported quarter. |
| Revenue growth YoY (qtr) | -48.0% | Latest quarter revenue vs the same quarter a year earlier. |
| Revenue growth QoQ (qtr) | -6.5% | Latest quarter revenue vs the previous quarter. |
| EPS growth YoY (qtr) | 1.1% | Latest quarter EPS vs the same quarter a year earlier. |
| EPS growth QoQ (qtr) | -13.8% | Latest quarter EPS vs the previous quarter. |
| Net income growth YoY (qtr) | -25.8% | Latest quarter net income vs the same quarter a year earlier. |
| Net income growth QoQ (qtr) | -19.6% | Latest quarter net income vs the previous quarter. |
| Gross margin (qtr) | — | Gross profit ÷ revenue in the latest quarter. |
| Operating margin (qtr) | -1,707.7% | Operating income ÷ revenue in the latest quarter. |
| Net margin (qtr) | -1,779.8% | Net income ÷ revenue in the latest quarter. |
| Revenue (TTM) | $52.89M | Revenue of the last four quarters. |
| Net income (TTM) | -$426.14M | Net income of the last four quarters. |
| EPS (TTM) | -3.33 | Sum of the last four quarters of diluted EPS. |
| Revenue growth (TTM) | -8.1% | Last four quarters of revenue vs the four quarters before. |
| EPS growth (TTM) | 22.0% | Last four quarters of EPS vs the four quarters before. |
| Net income growth (TTM) | 4.4% | Last four quarters of net income vs the four quarters before. |
Dividends & shareholder returns
| Dividend yield | 0.0% | Dividends paid per share over the last 12 months ÷ price. |
|---|---|---|
| Dividend / share (TTM) | — | Dividends per share paid over the last 12 months. |
| Payout ratio | — | Dividends per share ÷ EPS. Above 100% means the dividend exceeds earnings. |
| FCF payout ratio | — | Dividends ÷ free cash flow. |
| Dividend growth (1y) | — | Dividends per share vs the same 12-month window a year earlier. |
| Dividend CAGR (3y) | — | Annualised dividend growth over 3 years. |
| Dividend CAGR (5y) | — | Annualised dividend growth over 5 years. |
| Payments (12m) | — | Number of dividend payments in the last 12 months. |
| Last ex-dividend date | — | Most recent ex-dividend date. |
| Buyback yield | 0.0% | Share repurchases ÷ market cap. |
| Shareholder yield | 0.0% | Dividend yield + buyback yield. |
Profitability
| Gross margin | — | Gross profit ÷ revenue (latest fiscal year). |
|---|---|---|
| EBITDA margin | -637.2% | EBITDA ÷ revenue. |
| Operating margin | -651.7% | Operating income ÷ revenue. |
| Net margin | -609.9% | Net income ÷ revenue. |
| FCF margin | -585.0% | Free cash flow ÷ revenue. |
| ROE | -61.5% | Return on equity: net income ÷ shareholders' equity. Blank when equity is negative. |
| ROA | -49.0% | Return on assets: net income ÷ total assets. |
| ROIC | -67.5% | Return on invested capital: after-tax operating income ÷ (equity + debt − cash). |
Growth (annual)
| Revenue growth (annual) | 16.9% | Latest fiscal year revenue vs the year before. |
|---|---|---|
| Net income growth (annual) | 20.5% | Latest fiscal year net income vs the year before. |
| EPS growth (annual) | 27.4% | Latest fiscal year diluted EPS vs the year before. |
| Revenue CAGR (3y) | 9.1% | Annualised revenue growth over 3 fiscal years. |
| EPS CAGR (3y) | — | Annualised EPS growth over 3 fiscal years. |
Financial health
| Current ratio | 5.08 | Current assets ÷ current liabilities. Above 1 means short-term bills are covered. |
|---|---|---|
| Quick ratio | 5.08 | (Current assets − inventory) ÷ current liabilities. |
| Cash ratio | 1.50 | Cash ÷ current liabilities. |
| Debt / equity | 0.00 | Total debt ÷ shareholders' equity. Blank when equity is negative. |
| Debt / assets | 0.00 | Total debt ÷ total assets. |
| Debt / EBITDA | — | Total debt ÷ EBITDA: roughly how many years of earnings it takes to repay debt. |
| Net debt / EBITDA | — | (Debt − cash) ÷ EBITDA. Negative means more cash than debt. |
| Interest coverage | — | Operating income ÷ interest expense. |
Earnings quality
| FCF conversion | — | Free cash flow ÷ net income. Above 100% means profits turn into real cash. |
|---|---|---|
| Accruals ratio | -2.1% | (Net income − operating cash flow) ÷ assets. High values can signal low-quality earnings. |
| Stock comp % revenue | 118.5% | Share-based compensation ÷ revenue. |
| R&D % revenue | 574.6% | Research & development spending ÷ revenue. |
| SG&A % revenue | — | Selling, general & administrative expense ÷ revenue. |
| Tax rate used | 21.0% | Effective tax rate used for after-tax figures (capped 0–35%; 21% when unknown). |
Efficiency
| Asset turnover | 0.08 | Revenue ÷ total assets. |
|---|---|---|
| Days sales outstanding | 51 | Average days to collect payment from customers. |
| Days inventory | — | Average days inventory is held. |
| Days payables | — | Average days to pay suppliers. |
Trading & momentum
| 52-week high | $18.48 | Highest price in the last 52 weeks. |
|---|---|---|
| 52-week low | $7.90 | Lowest price in the last 52 weeks. |
| From 52-week high | -47.1% | How far below the 52-week high the price is (0% = at the high). |
| Above 52-week low | 23.8% | How far above the 52-week low the price is. |
| Avg volume (30d) | 3.29M | Average shares traded per day over the last 30 days. |
| Avg $ volume (30d) | $37.05M | Average dollars traded per day over the last 30 days: a liquidity measure. |
Scores
| Piotroski F-score | 3 | Nine yes/no tests of profitability, leverage and efficiency. 8–9 is strong, 0–2 is weak. Missing data counts as a fail. |
|---|---|---|
| Altman Z-score | -0.53 | Bankruptcy-risk score. Above 2.99 is safe, below 1.81 is distress. Not meaningful for banks and insurers. |
Reported figures (latest fiscal year)
| Revenue | $67.67M | Revenue of the latest fiscal year. |
|---|---|---|
| Net income | -$412.69M | Net income of the latest fiscal year. |
| Diluted EPS | -3.81 | Diluted earnings per share of the latest fiscal year. |
| EBITDA | -$431.22M | Operating income + depreciation & amortization. |
| Free cash flow | -$395.87M | Operating cash flow − capital spending. |
| Total debt | $0 | Long-term plus current debt. |
| Cash | $155.46M | Cash and equivalents. |
| Equity | $671.39M | Shareholders' equity. |
| Total assets | $842.13M | Total assets. |